Iambic Therapeutics, Inc. (IAM)
Company
Iambic Therapeutics, Inc. (IAM)
Oct 15, 2026
Biotechnology
Initial Public Offering / IPOIPO
Prospectus volume (424B4)150 m USD9,375,000 shares · 16 USD/share
IPO closed (8-K)172.5 m USD10,781,250 shares · 16 USD/share
We are a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry. Our mission is to make better technology for better medicines. We do this by integrating leading proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation. We call this approach molecular superintelligence.







